300204SZSE

Announcement on Polyethylene Glycol 3350 Powder Obtaining Drug Registration Certificate

✨ AI Summary

Shanshen (Beijing) Pharmaceutical Co., Ltd. announced it has received a Drug Registration Certificate for Polyethylene Glycol 3350 Powder from the NMPA. This approval allows the company to produce and sell the drug in China, expanding its product pipeline and market competitiveness. The drug is indicated for occasional constipation.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300204 Stock Abbreviation: Shanshen Announcement No.: 2026-011

Shanshen (Beijing) Pharmaceutical Co., Ltd. Announcement on Polyethylene Glycol 3350 Powder Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.

Recently, Shanshen (Beijing) Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanshen" or "the Company") received the Drug Registration Certificate for Polyethylene Glycol 3350 Powder, approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), obtaining the drug production registration approval. The relevant situation is hereby announced as follows:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.